World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
50
Citations
15146
World Ranking
17442
National Ranking
498

Overview

Guillaume Lessene is affiliated with the Walter and Eliza Hall Institute of Medical Research in Australia. Their research primarily focuses on biochemistry, genetics, and molecular biology, with significant contributions to medicine. The subfields of study in which they have published include molecular biology, oncology, immunology, infectious diseases, and genetics.

Lessene's work often centers on cellular and molecular mechanisms, particularly those related to cell death and immune responses. The main topics of their research include:

  • Cell death mechanisms and regulation
  • Interferon and immune responses
  • SARS-CoV-2 and COVID-19 research
  • Protein degradation and inhibitors
  • Ubiquitin and proteasome pathways
  • Cancer-related molecular pathways
  • Chronic lymphocytic leukemia research

Among their recent publications are:

  • "Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2," 2020, The EMBO Journal
  • "MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis," 2020, Nature Communications
  • "The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs," 2021, Nature Reviews. Cancer
  • "Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis," 2021, Nature Communications
  • "Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia," 2022, Blood

Lessene has collaborated extensively with several co-authors, including Peter E. Czabotar, David C.S. Huang, Kym N. Lowes, Andreas Strasser, and Mark F. van Delft.

Their publications are frequently found in several notable venues such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Cell Death and Differentiation
  • Cell Death and Disease
  • The EMBO Journal

Best Publications

  • Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

    Peter E Czabotar;Guillaume Lessene;Andreas Strasser;Jerry M Adams

  • The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

    András Kotschy;Zoltán Szlavik;James Murray;James Davidson

  • Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production

    Michael J. White;Michael J. White;Kate McArthur;Kate McArthur;Donald Metcalf;Donald Metcalf;Rachael M. Lane

  • BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis

    Kate McArthur;Kate McArthur;Kate McArthur;Lachlan W. Whitehead;Lachlan W. Whitehead;John M. Heddleston;Lucy Li

  • BCL-2 family antagonists for cancer therapy

    Guillaume Lessene;Peter E. Czabotar;Peter M. Colman

  • Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death

    Joanne M. Hildebrand;Maria C. Tanzer;Isabelle S. Lucet;Isabelle S. Lucet;Samuel N. Young

  • Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.

    Theresa Klemm;Gregor Ebert;Dale J Calleja;Cody C Allison

  • Structure-guided design of a selective BCL-XL inhibitor

    Guillaume Lessene;Guillaume Lessene;Peter Edward Czabotar;Peter Edward Czabotar;Brad Sleebs;Brad Sleebs;Kerry Zobel

  • Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

    Zhi-Fu Tao;Lisa Hasvold;Le Wang;Xilu Wang

  • BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

    Delphine Merino;Gemma L. Kelly;Guillaume Lessene;Andrew H. Wei

  • MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis

    Andre L Samson;Andre L Samson;Ying Zhang;Ying Zhang;Niall D Geoghegan;Niall D Geoghegan;Xavier J Gavin

  • The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.

    Sarah T Diepstraten;Mary Ann Anderson;Peter E Czabotar;Peter E Czabotar;Guillaume Lessene;Guillaume Lessene

  • Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

    Richard W. Birkinshaw;Richard W. Birkinshaw;Jia-nan Gong;Jia-nan Gong;Cindy S. Luo;Cindy S. Luo;Daisy Lio;Daisy Lio

  • The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1β Activation

    James E. Vince;James E. Vince;Dominic De Nardo;Dominic De Nardo;Wenqing Gao;Angelina J. Vince

  • Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

    Delphine Merino;Delphine Merino;James R. Whittle;James R. Whittle;James R. Whittle;François Vaillant;François Vaillant;Antonin Serrano;Antonin Serrano

  • Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

    T. C. Teh;T. C. Teh;N. Y. Nguyen;D. M. Moujalled;D. Segal;D. Segal

  • Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis.

    Emma J. Petrie;Emma J. Petrie;Jarrod J. Sandow;Jarrod J. Sandow;Annette V. Jacobsen;Annette V. Jacobsen;Brian J. Smith

  • HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death.

    A V Jacobsen;A V Jacobsen;K N Lowes;K N Lowes;M C Tanzer;M C Tanzer;I S Lucet;I S Lucet

  • Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

    Donia M. Moujalled;Donia M. Moujalled;Giovanna Pomilio;Giovanna Pomilio;Corina Ghiurau;Adam Ivey

  • Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

    Jia Nan Gong;Jia Nan Gong;Tiffany Khong;David Segal;David Segal;Yuan Yao;Yuan Yao;Yuan Yao

Frequent Co-Authors

Peter E. Czabotar
Peter E. Czabotar Walter and Eliza Hall Institute of Medical Research
David C. S. Huang
David C. S. Huang Walter and Eliza Hall Institute of Medical Research
Jonathan B. Baell
Jonathan B. Baell Monash University
Peter M. Colman
Peter M. Colman Walter and Eliza Hall Institute of Medical Research
Brian J. Smith
Brian J. Smith QIMR Berghofer Medical Research Institute
Marco J. Herold
Marco J. Herold Walter and Eliza Hall Institute of Medical Research
Andreas Strasser
Andreas Strasser Walter and Eliza Hall Institute of Medical Research
James M. Murphy
James M. Murphy Walter and Eliza Hall Institute of Medical Research
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Guillaume Lessene

Trending Scientists